The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/1000. Detects a band of approximately 48 kDa (predicted molecular weight: 45 kDa).
Use at an assay dependent concentration.
FunctionDOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK2 may modulate the cellular proliferation induced by IL-4, as well as IL-2 and IL-3. May be involved in modulating Bcr-Abl signaling. Attenuates EGF-stimulated MAP kinase activation.
Tissue specificityHighly expressed in peripheral blood leukocytes, lymph nodes and spleen. Lower expression in thymus, bone marrow and fetal liver.
Sequence similaritiesBelongs to the DOK family. Type A subfamily. Contains 1 IRS-type PTB domain. Contains 1 PH domain.
DomainPTB domain mediates receptor interaction.
Post-translational modificationsOn immunoreceptor stimulation, phosphorylated on C-terminal tyrosine residues. Phosphorylation on Tyr-345 is required for binding to the SH2 domain of NCK. Phosphorylation on both Tyr-271 and Tyr-299 is required for interaction with RASGAP.
Ab47507 at 1/50 dilution staining paraffin-embedded
human breast carcinoma tissue; Left without and right with imunising peptide.
References for Anti-DOK2 antibody (ab47507)
This product has been referenced in:
Ren Y et al. Aberrant CD200/CD200R1 expression and its potential role in Th17 cell differentiation, chemotaxis and osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford)N/A:N/A (2014).
Read more (PubMed: 25261692) »
Li Y et al. Aberrant CD200/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity. Arthritis Res Ther14:R123 (2012).
Read more (PubMed: 22621248) »